JP2018530568A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018530568A5 JP2018530568A5 JP2018517898A JP2018517898A JP2018530568A5 JP 2018530568 A5 JP2018530568 A5 JP 2018530568A5 JP 2018517898 A JP2018517898 A JP 2018517898A JP 2018517898 A JP2018517898 A JP 2018517898A JP 2018530568 A5 JP2018530568 A5 JP 2018530568A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- agonist
- composition
- acting
- long
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000556 agonist Substances 0.000 claims description 34
- 102000003812 Interleukin-15 Human genes 0.000 claims description 27
- 206010028980 Neoplasm Diseases 0.000 claims description 26
- 201000011510 cancer Diseases 0.000 claims description 26
- 206010009944 Colon cancer Diseases 0.000 claims description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 208000026310 Breast neoplasm Diseases 0.000 claims description 6
- 230000004913 activation Effects 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 206010004593 Bile duct cancer Diseases 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 208000017604 Hodgkin disease Diseases 0.000 claims description 4
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000026900 bile duct neoplasm Diseases 0.000 claims description 4
- 208000006990 cholangiocarcinoma Diseases 0.000 claims description 4
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 claims description 4
- 201000004101 esophageal cancer Diseases 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000001441 melanoma Diseases 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 208000006468 Adrenal Cortex Neoplasms Diseases 0.000 claims description 3
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 3
- 208000005450 Maxillary Sinus Neoplasms Diseases 0.000 claims description 3
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 3
- 201000010881 cervical cancer Diseases 0.000 claims description 3
- 201000004488 maxillary sinus cancer Diseases 0.000 claims description 3
- 208000019303 maxillary sinus carcinoma Diseases 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims 10
- 229920003169 water-soluble polymer Polymers 0.000 claims 10
- 150000003839 salts Chemical class 0.000 claims 9
- 108010002350 Interleukin-2 Proteins 0.000 claims 7
- 230000003213 activating effect Effects 0.000 claims 7
- 229920001223 polyethylene glycol Polymers 0.000 claims 6
- 229920000642 polymer Polymers 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 5
- 102000004556 Interleukin-15 Receptors Human genes 0.000 claims 3
- 108010017535 Interleukin-15 Receptors Proteins 0.000 claims 3
- 108700025316 aldesleukin Proteins 0.000 claims 2
- 229960005310 aldesleukin Drugs 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 230000001919 adrenal effect Effects 0.000 claims 1
- 230000001054 cortical effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 9
- 102000008616 interleukin-15 receptor activity proteins Human genes 0.000 description 2
- 108040002039 interleukin-15 receptor activity proteins Proteins 0.000 description 2
- 230000000694 effects Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562239207P | 2015-10-08 | 2015-10-08 | |
| US62/239,207 | 2015-10-08 | ||
| PCT/US2016/056088 WO2017062832A1 (en) | 2015-10-08 | 2016-10-07 | Combination of an il-2rbeta-selective agonist and a long-acting il-15 agonist |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021016606A Division JP2021066748A (ja) | 2015-10-08 | 2021-02-04 | ＩＬ−２Ｒβ選択的作動薬と長時間作用型ＩＬ−１５作動薬との併用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018530568A JP2018530568A (ja) | 2018-10-18 |
| JP2018530568A5 true JP2018530568A5 (OSRAM) | 2019-11-14 |
| JP7407511B2 JP7407511B2 (ja) | 2024-01-04 |
Family
ID=57249859
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018517898A Active JP7407511B2 (ja) | 2015-10-08 | 2016-10-07 | ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用 |
| JP2021016606A Withdrawn JP2021066748A (ja) | 2015-10-08 | 2021-02-04 | ＩＬ−２Ｒβ選択的作動薬と長時間作用型ＩＬ−１５作動薬との併用 |
| JP2023085387A Withdrawn JP2023099731A (ja) | 2015-10-08 | 2023-05-24 | ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021016606A Withdrawn JP2021066748A (ja) | 2015-10-08 | 2021-02-04 | ＩＬ−２Ｒβ選択的作動薬と長時間作用型ＩＬ−１５作動薬との併用 |
| JP2023085387A Withdrawn JP2023099731A (ja) | 2015-10-08 | 2023-05-24 | ＩＬ－２Ｒβ選択的作動薬と長時間作用型ＩＬ－１５作動薬との併用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US12233104B2 (OSRAM) |
| EP (1) | EP3359182B1 (OSRAM) |
| JP (3) | JP7407511B2 (OSRAM) |
| KR (1) | KR102861230B1 (OSRAM) |
| CN (1) | CN108135978A (OSRAM) |
| AU (1) | AU2016335860B2 (OSRAM) |
| IL (1) | IL258456B (OSRAM) |
| MA (1) | MA47290A (OSRAM) |
| MX (1) | MX2018004296A (OSRAM) |
| WO (1) | WO2017062832A1 (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2018270926C1 (en) * | 2017-05-15 | 2022-10-27 | Nektar Therapeutics | Long-acting interleukin-15 receptor agonists and related immunotherapeutic compositions and methods |
| US11248025B2 (en) | 2019-06-03 | 2022-02-15 | Medikine, Inc. | IL-2alpha receptor subunit binding compounds |
| WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
| US20250222027A1 (en) | 2022-04-01 | 2025-07-10 | Sana Biotechnology, Inc. | Cytokine receptor agonist and viral vector combination therapies |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4401756A (en) | 1981-04-14 | 1983-08-30 | Immunex Corporation | Process for preparing human interleukin 2 |
| US4569790A (en) | 1984-03-28 | 1986-02-11 | Cetus Corporation | Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions |
| US5116943A (en) | 1985-01-18 | 1992-05-26 | Cetus Corporation | Oxidation-resistant muteins of Il-2 and other protein |
| WO1987000056A1 (en) | 1985-06-26 | 1987-01-15 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| US4705848A (en) | 1986-06-02 | 1987-11-10 | International Minerals & Chemical Corp. | Isolation of bioactive, monomeric growth hormone |
| US5078997A (en) | 1988-07-13 | 1992-01-07 | Cetus Corporation | Pharmaceutical composition for interleukin-2 containing physiologically compatible stabilizers |
| US4902502A (en) | 1989-01-23 | 1990-02-20 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5089261A (en) | 1989-01-23 | 1992-02-18 | Cetus Corporation | Preparation of a polymer/interleukin-2 conjugate |
| US5153310A (en) | 1989-02-28 | 1992-10-06 | Du Pont Merck Pharmaceutical Company | Il-2 analogs containing n-linked glycosylation sites |
| US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
| IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
| US5595732A (en) | 1991-03-25 | 1997-01-21 | Hoffmann-La Roche Inc. | Polyethylene-protein conjugates |
| US6077519A (en) | 1993-01-29 | 2000-06-20 | University Of Pittsburgh | Methods for isolation and use of T cell epitopes eluted from viable cells in vaccines for treating cancer patients |
| US5446090A (en) | 1993-11-12 | 1995-08-29 | Shearwater Polymers, Inc. | Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules |
| EP0728210B1 (en) * | 1993-11-12 | 2005-04-13 | Gilead Sciences, Inc. | Thrombin mutants |
| US5635597A (en) | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
| US5932462A (en) | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
| US5795966A (en) | 1995-02-22 | 1998-08-18 | Immunex Corp | Antagonists of interleukin-15 |
| US7008624B1 (en) | 1995-02-22 | 2006-03-07 | Immunex Corporation | Antagonists of interleukin-15 |
| US6034072A (en) | 1997-02-10 | 2000-03-07 | Genemedicine, Inc. | IL-2 gene expression and delivery systems and uses |
| US6180095B1 (en) | 1997-12-17 | 2001-01-30 | Enzon, Inc. | Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents |
| ATE268609T1 (de) | 1998-03-12 | 2004-06-15 | Nektar Therapeutics Al Corp | Polyethylenglycolderivate mit benachbarten reaktiven gruppen |
| DZ2788A1 (fr) | 1998-05-15 | 2003-12-01 | Bayer Ag | Agonistes et antagonistes selectifs à IL-2. |
| US6168785B1 (en) | 1998-07-16 | 2001-01-02 | Institut Pasteur | Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents |
| AU2001238595A1 (en) | 2000-02-22 | 2001-09-03 | Shearwater Corporation | N-maleimidyl polymer derivatives |
| US6689353B1 (en) | 2000-06-28 | 2004-02-10 | Bayer Pharmaceuticals Corporation | Stabilized interleukin 2 |
| CN1317301C (zh) | 2000-09-14 | 2007-05-23 | 贝斯以色列护理医疗中心有限公司 | Il－2－和il－15－介导的t细胞应答的调节 |
| WO2002036169A2 (en) | 2000-10-31 | 2002-05-10 | Pr Pharmaceuticals, Inc. | Methods and compositions for enhanced delivery of bioactive molecules |
| FR2826365B1 (fr) | 2001-06-20 | 2003-09-26 | Oreal | Compositions cosmetiques photoprotectrices contenant des derives amides, sulfonamides ou carbamates aromatiques d'acrylonitrile et nouveaux derives amides, sulfonamides ou carbamates d'acrylonitrile |
| AP2005003246A0 (en) | 2002-09-09 | 2005-03-31 | Nektar Therapeutics Al Corp | Water-soluble polymer alkanals |
| US20040136952A1 (en) | 2002-12-26 | 2004-07-15 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
| KR101025143B1 (ko) | 2002-12-31 | 2011-04-01 | 넥타르 테라퓨틱스 | 가수분해상으로 안정한 말레이미드－종결 중합체 |
| MXPA05007348A (es) | 2003-01-06 | 2005-10-05 | Nektar Therapeutics Al Corp | Derivados de polimeros solubles en agua tiol-selectivos. |
| PL1620118T3 (pl) | 2003-04-08 | 2014-11-28 | Yeda Res & Dev | Leki odwracalnie pegylowane |
| NZ541374A (en) | 2003-05-23 | 2008-09-26 | Nektar Therapeutics Al Corp | PEG derivatives having an amidocarbonate linkage |
| US7569215B2 (en) | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| US20050069521A1 (en) * | 2003-08-28 | 2005-03-31 | Emd Lexigen Research Center Corp. | Enhancing the circulating half-life of interleukin-2 proteins |
| AU2004275871A1 (en) | 2003-09-25 | 2005-04-07 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| CN1913925A (zh) | 2003-12-10 | 2007-02-14 | 尼克塔治疗亚拉巴马公司 | 含有两组不同聚合物－活性剂缀合物的组合物 |
| AR050293A1 (es) | 2004-08-11 | 2006-10-11 | Moll Tomas | Polipeptidos de interleuquina-15 mutante |
| AU2005335217A1 (en) | 2004-10-05 | 2007-02-15 | Ochsner Clinic Foundation | Enhancement of B cell proliferation by IL-15 |
| ES2289663T3 (es) | 2005-02-07 | 2008-02-01 | Novartis Vaccines And Diagnostics, Inc. | Preparacion de aldesleucina para uso farmaceutico. |
| JP4560629B2 (ja) | 2005-03-31 | 2010-10-13 | 国立大学法人 筑波大学 | 腫瘍壊死誘導療法の抗腫瘍効果増強剤 |
| US20060257361A1 (en) * | 2005-04-12 | 2006-11-16 | Government Of The Us, As Represented By The Secretary, Department Of Health And Human Services | Novel form of interleukin-15, Fc-IL-15, and methods of use |
| EP2390267B1 (en) | 2005-06-07 | 2013-06-05 | ESBATech - a Novartis Company LLC | Stable and soluble antibodies inhibiting TNF(alpha) |
| EP2279758B1 (en) | 2005-06-16 | 2015-02-25 | Nektar Therapeutics | Conjugates having a degradable linkage and polymeric reagents useful in preparing such conjugates |
| JP5096363B2 (ja) | 2005-12-16 | 2012-12-12 | ネクター セラピューティックス | Ｇｌｐ−１のポリマ複合体 |
| CA2634167C (en) * | 2005-12-21 | 2015-06-16 | Sentoclone Ab | Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer |
| WO2007117685A2 (en) | 2006-04-07 | 2007-10-18 | Nektar Therapeutics Al, Corporation | Conjugates of an anti-tnf-alpha antibody |
| CN101104077A (zh) | 2006-07-12 | 2008-01-16 | 北京紫辰医药生物技术研究所 | 重组人白介素-2与聚乙二醇的偶合物 |
| CN101588819B (zh) * | 2006-12-27 | 2012-11-21 | 尼克塔治疗公司 | 具有可释放的键合的ix因子部分-聚合物轭合物 |
| CA2671676C (en) | 2006-12-27 | 2014-04-22 | Baxter Healthcare Sa | Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage |
| WO2008106186A2 (en) | 2007-02-28 | 2008-09-04 | Serina Therapeutics, Inc. | Activated polyoxazolines and compositions comprising the same |
| RU2010136023A (ru) | 2008-02-01 | 2012-03-10 | Асцендис Фарма Ас (Dk) | Пролекарство, содержащее саморасщепляемый линкер |
| KR20090103209A (ko) | 2008-03-27 | 2009-10-01 | (주)한국비엠아이 | 사람 인터루킨-2 동종체 |
| WO2009135031A1 (en) * | 2008-04-30 | 2009-11-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic | Substituted il-15 |
| EP2293818B1 (en) | 2008-05-16 | 2021-04-28 | Nektar Therapeutics | Conjugates of butyrylcholinesterase and a polymer |
| WO2010014258A2 (en) | 2008-08-01 | 2010-02-04 | Nektar Therapeutics Al, Corporation | Conjugates having a releasable linkage |
| EP2898900B1 (en) | 2008-09-19 | 2017-11-15 | Nektar Therapeutics | Polymer conjugates of ziconotide |
| WO2010048184A2 (en) | 2008-10-21 | 2010-04-29 | Baxter International Inc. | Methods for determining active ingredients in pro-drug peg protein conjugates with releasable peg reagents (in vitro de-pegylation) |
| WO2012016131A1 (en) | 2010-07-30 | 2012-02-02 | Baxter International Inc. | Nucleophilic catalysts for oxime linkage |
| KR20200070407A (ko) | 2010-11-12 | 2020-06-17 | 넥타르 테라퓨틱스 | Ｉｌ-2 부분 및 중합체의 접합체 |
| WO2013020079A2 (en) * | 2011-08-04 | 2013-02-07 | Nektar Therapeutics | Conjugates of an il-11 moiety and a polymer |
| US20150017120A1 (en) | 2013-06-13 | 2015-01-15 | Massachusetts Institute Of Technology | Synergistic tumor treatment with extended-pk il-2 and adoptive cell therapy |
| HRP20210377T1 (hr) * | 2014-02-21 | 2021-04-16 | Nektar Therapeutics | Il-2rbeta-selektivni agonisti u kombinaciji s anti-ctla-4 protutijelom ili anti-pd-1 protutijelom |
| MA39711A (fr) * | 2014-04-03 | 2015-10-08 | Nektar Therapeutics | Conjugués d'une fraction d'il-15 et d'un polymère |
-
2016
- 2016-10-07 JP JP2018517898A patent/JP7407511B2/ja active Active
- 2016-10-07 AU AU2016335860A patent/AU2016335860B2/en active Active
- 2016-10-07 MX MX2018004296A patent/MX2018004296A/es unknown
- 2016-10-07 MA MA047290A patent/MA47290A/fr unknown
- 2016-10-07 CN CN201680058497.XA patent/CN108135978A/zh active Pending
- 2016-10-07 US US15/765,207 patent/US12233104B2/en active Active
- 2016-10-07 EP EP16791713.7A patent/EP3359182B1/en active Active
- 2016-10-07 KR KR1020187011922A patent/KR102861230B1/ko active Active
- 2016-10-07 WO PCT/US2016/056088 patent/WO2017062832A1/en not_active Ceased
-
2018
- 2018-03-29 IL IL258456A patent/IL258456B/en unknown
-
2021
- 2021-02-04 JP JP2021016606A patent/JP2021066748A/ja not_active Withdrawn
-
2023
- 2023-05-24 JP JP2023085387A patent/JP2023099731A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019534308A5 (OSRAM) | ||
| US11554178B2 (en) | Compositions and methods of modulating macrophage activity | |
| JP2016533344A5 (OSRAM) | ||
| JP2019509339A5 (OSRAM) | ||
| JP2019515908A5 (OSRAM) | ||
| JP2018530568A5 (OSRAM) | ||
| JP2001247459A5 (OSRAM) | ||
| JP2020519676A5 (OSRAM) | ||
| JP2020537501A5 (OSRAM) | ||
| JP2010511713A (ja) | 薬物送達 | |
| JP2016224056A5 (OSRAM) | ||
| Park et al. | Personalized combination nano-immunotherapy for robust induction and tumor infiltration of CD8+ T cells | |
| JP2007524613A5 (OSRAM) | ||
| JP2019505585A5 (OSRAM) | ||
| TWI641374B (zh) | 含低用量伊立替康鹽酸鹽水合物之抗腫瘤劑 | |
| US20210353670A1 (en) | Nanoparticles for use as a therapeutic vaccine | |
| JP2021505541A5 (OSRAM) | ||
| JP2012503602A5 (OSRAM) | ||
| JP2020518610A5 (OSRAM) | ||
| JP2019509986A (ja) | トリプトライドのグルコース・コンジュゲート、その類縁体及び使用 | |
| JP2020534300A5 (OSRAM) | ||
| JP2009510165A5 (OSRAM) | ||
| CA2596084A1 (en) | Treatment of metastasized tumors with quinolinone benzimidazole compounds | |
| JP2008528617A5 (OSRAM) | ||
| WO2009142328A1 (ja) | カンプトテシン高分子誘導体及びその用途 |